# US 2008/0306105 A1 · Deuterium-enriched moxifloxacin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306105 A1
- Document ID: US20080306105A1
- Status: Published application
- Kind: A1
- Application number: 11/758,690
- Filed: 2007-06-06
- Published: 2008-12-11
- Earliest claimed: 2007-06-06
- Assignees: Protia, LLC
- Inventors: Anthony W. Czarnik
- Web page: https://patentgrep.com/patent/US20080306105A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application describes deuterium-enriched moxifloxacin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

## Claims

### Claim 1

A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
wherein R1—R24 are independently selected from H and D; and the abundance of deuterium in R1—R24 is at least 4%.

### Claim 2 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the abundance of deuterium in R1—R24 is selected from at least 4%, at least 8%, at least 13%, at least 17%, at least 21%, at least 25%, at least 29%, at least 33%, at least 38%, at least 42%, at least 46%, at least 50%, at least 54%, at least 58%, at least 63%, at least 67%, at least 71%, at least 75%, at least 79%, at least 83%, at least 88%, at least 92%, at least 96%, and 100%.

### Claim 3 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the abundance of deuterium in R1—R2 is selected from at least 50% and 100%.

### Claim 4 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the abundance of deuterium in R3—R14 is selected from at least 8%, at least 17%, at least 25%, at least 33%, at least 42%, at least 50%, at least 58%, at least 67%, at least 75%, at least 83%, at least 92%, and 100%.

### Claim 5 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the abundance of deuterium in R15 is selected from 100%.

### Claim 6 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the abundance of deuterium in R16—R18 is selected from at least 33%, at least 67%, and 100%.

### Claim 7 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the abundance of deuterium in R19—R23 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

### Claim 8 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the abundance of deuterium in R24 is selected from 100%.

### Claim 9 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is selected from compounds 1-7 of Table 1:

### Claim 10 (depends on 1)

A deuterium-enriched compound of claim 1, wherein the compound is selected from compounds 8-14 of Table 2:

### Claim 11

An isolated deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
wherein R1—R24 are independently selected from H and D; and the abundance of deuterium in R1—R24 is at least 4%.

### Claim 12 (depends on 11)

An isolated deuterium-enriched compound of claim 11, wherein the abundance of deuterium in R1—R24 is selected from at least 4%, at least 8%, at least 13%, at least 17%, at least 21%, at least 25%, at least 29%, at least 33%, at least 38%, at least 42%, at least 46%, at least 50%, at least 54%, at least 58%, at least 63%, at least 67%, at least 71%, at least 75%, at least 79%, at least 83%, at least 88%, at least 92%, at least 96%, and 100%.

### Claim 13 (depends on 11)

An isolated deuterium-enriched compound of claim 11, wherein the abundance of deuterium in R1—R2 is selected from at least 50% and 100%.

### Claim 14 (depends on 11)

An isolated deuterium-enriched compound of claim 11, wherein the abundance of deuterium in R3—R14 is selected from at least 8%, at least 17%, at least 25%, at least 33%, at least 42%, at least 50%, at least 58%, at least 67%, at least 75%, at least 83%, at least 92%, and 100%.

### Claim 15 (depends on 11)

An isolated deuterium-enriched compound of claim 11, wherein the abundance of deuterium in R15 is selected from 100%.

### Claim 16 (depends on 11)

An isolated deuterium-enriched compound of claim 11, wherein the abundance of deuterium in R16—R18 is selected from at least 33%, at least 67%, and 100%.

### Claim 17 (depends on 11)

An isolated deuterium-enriched compound of claim 11, wherein the abundance of deuterium in R19—R23 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

### Claim 18 (depends on 11)

An isolated deuterium-enriched compound of claim 11, wherein the abundance of deuterium in R24 is selected from 100%.

### Claim 19 (depends on 11)

An isolated deuterium-enriched compound of claim 11, wherein the compound is selected from compounds 1-7 of Table 1:

### Claim 20 (depends on 11)

An isolated deuterium-enriched compound of claim 11, wherein the compound is selected from compounds 8-14 of Table 2:

### Claim 21

A mixture of deuterium-enriched compounds of formula I or a pharmaceutically acceptable salt thereof:
wherein R1—R24 are independently selected from H and D; and the abundance of deuterium in R1—R24 is at least 4%.

### Claim 22 (depends on 21)

A mixture of deuterium-enriched compounds of claim 21, wherein the abundance of deuterium in R1—R24 is selected from at least 4%, at least 8%, at least 13%, at least 17%, at least 21%, at least 25%, at least 29%, at least 33%, at least 38%, at least 42%, at least 46%, at least 50%, at least 54%, at least 58%, at least 63%, at least 67%, at least 71%, at least 75%, at least 79%, at least 83%, at least 88%, at least 92%, at least 96%, and 100%.

### Claim 23 (depends on 21)

A mixture of deuterium-enriched compounds of claim 21, wherein the abundance of deuterium in R1—R2 is selected from at least 50% and 100%.

### Claim 24 (depends on 21)

A mixture of deuterium-enriched compounds of claim 21, wherein the abundance of deuterium in R3—R14 is selected from at least 8%, at least 17%, at least 25%, at least 33%, at least 42%, at least 50%, at least 58%, at least 67%, at least 75%, at least 83%, at least 92%, and 100%.

### Claim 25 (depends on 21)

A mixture of deuterium-enriched compounds of claim 21, wherein the abundance of deuterium in R15 is selected from 100%.

### Claim 26 (depends on 21)

A mixture of deuterium-enriched compounds of claim 21, wherein the abundance of deuterium in R16—R18 is selected from at least 33%, at least 67%, and 100%.

### Claim 27 (depends on 21)

A mixture of deuterium-enriched compounds of claim 21, wherein the abundance of deuterium in R19—R23 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.

### Claim 28 (depends on 21)

A mixture of deuterium-enriched compounds of claim 21, wherein the abundance of deuterium in R24 is selected from 100%.

### Claim 29 (depends on 21)

A mixture of deuterium-enriched compounds of claim 21, wherein the compound is selected from compounds 1-7 of Table 1:

### Claim 30 (depends on 21)

A mixture of deuterium-enriched compounds of claim 21, wherein the compound is selected from compounds 8-14 of Table 2:

### Claim 31 (depends on 1)

A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

### Claim 32 (depends on 1)

A method for treating a disease selected from acute sinusitis, acute exacerbations of chronic bronchitis and community-acquired pneumonia, skin structure infections, complicated intra-abdominal infections, and conjunctival infections comprising:
administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.
